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67* Preclinical evaluation of preventive hypertonic saline therapy for
cystic ﬁbrosis-like lung disease in mice
Z. Zhou1, S.Y. Graeber1, J. Schatterny1, S. Hirtz1, M. Mall1. 1Division of
Pediatric Pulmonology & Allergy and Cystic Fibrosis Center, Department of
Pediatrics III, Heidelberg, Germany
Dehydration of airway surfaces and reduced mucus clearance due to ENaC-mediated
increased airway Na+ absorption plays an important role in the pathogenesis of
cystic ﬁbrosis (CF) lung disease in patients and causes CF-like lung disease
in bENaC-transgenic (bENaC-Tg) mice. Previous clinic trials demonstrated that
inhalation of hypertonic saline (HS, NaCl 7%) improved mucus clearance and lung
function in CF patients (Donaldson SH et al., 2006), and pilot studies demonstrated
that inhalation of HS is well tolerated in young children with CF (Dellon EP et
al., 2008). However, effects of HS therapy on airway mucus obstruction and airway
inﬂammation, and the beneﬁts of preventive HS treatment have not been studied.
To determine the effects of preventive and late HS therapy on these characteristic
features of CF-like lung disease in vivo, we used newborn or 4-week old bENaC-
Tg mice and wild-type littermates and applied intrapulmonary instillation of HS
or vehicle alone for 2 weeks. Subsequently, mice were euthanized, bronchoalveolar
lavage performed, and lungs processed for histology. We demonstrate that both
preventive and late HS treatment provide an effective mucolytic therapy for CF-like
lung disease. However, HS promoted airway inﬂammation in neonates and had no
therapeutic effect on airway inﬂammation in adult bENaC-Tg mice with established
CF-like lung disease. These results suggest that potential proinﬂammatory side
effects of early HS treatment should be evaluated before using HS as treatment for
CF infants, and that combined mucolytic and anti-inﬂammatory therapies may be
necessary for the treatment of CF lung disease.
Supported by EC (MEXT-2004–013666).
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The hypothiocyanite (OSCN−) and Lactoferrin (Lf) system, described as the major
human host defense system against infection, is completely defective in cystic
ﬁbrosis (CF) patients. Difﬁculty breathing is the most serious symptom, resulting
from frequent lung infections which were mostly treated but not completely cured.
Meveol®, [Lf/OSCN−] complex, is a new anti-infectious orphan drug developed
by Alaxia for CF patients. The aim of this study was to verify the antimicrobial
activity of Meveol® and to investigate the feasibility to develop an aerosol Meveol®
treatment.
First, [Lf/OSCN−] activity was tested in vivo on a mice model infected with
P. aeruginosa mucoı¨d (Pam), and, in vitro, on Mycobacterium abscessus (Ma),
an emerging lung pathogen. In a second time, Meveol® (5mL) was nebulized with
jet and mesh nebulizers. Aerosols were tested for OSCN− and Lf stability and then
characterized in terms of particle size distribution, inhalable and respirable mass.
Mice treated with [Lf/OSCN−] presented a signiﬁcantly lower level of lung col-
onization (1.5±0.5 logCFU Pam/g vs. 3.08±0.4 logCFU Pam/g in control mice).
Moreover, [Lf/OSCN−] has allowed the total eradication of Ma, within 48 h of
in vitro incubation. After nebulization, OSCN− and Lf are both preserved in the
aerosol form of Meveol®. The 57.3±1.4% of inhalable fraction obtained with the
Aeroneb®Go/IdehalerPocket® nebulizer has conducted to select this device for
further clinical development.
Meveol® can be efﬁciently administered by inhalation route. Thanks to its wide
antimicrobial activity, aerosols of Meveol® could contribute to daily improve the
quality of life of CF patients, reducing antibiotic resistances.
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Phosphodiesterase type 5 inhibitors, such as sildenaﬁl and vardenaﬁl, are used for
the treatment of male erectile dysfunction and are able to activate chloride transport
in CF mice homozygous for the F508del-CFTR mutation (Lubamba et al., 2008).
It has been reported that sildenaﬁl reduces neutrophil lung inﬁltration in mice
aerogenously infected with Pseudomonas aeruginosa (Poschet et al., 2007). We
tested the hypothesis that vardenaﬁl modulates the inﬂammatory response in CF
airways.
The effect of vardenaﬁl pretreatment (0.14mg/kg/day), given by a single intraperi-
toneal injection, was evaluated, after induction of inﬂammation by intratracheal
instillation of lipopolysaccharide from P. aeruginosa (LPS), on cellular and molec-
ular markers of lung inﬂammation in CF-F508del and control mice.
The effect of LPS administration on cellular responses (macrophage and neutrophil)
appeared to be higher in CF as compared to wild-type mice. In both CF-F508del and
wild-type mice, vardenaﬁl attenuated cellular inﬁltration, tumor necrosis factor-a
and macrophage inﬂammatory protein-2 (MIP2) release in LPS-induced inﬂamma-
tion. Vardenaﬁl reversed the inﬂammatory parameters nearly back to control values.
Our ﬁndings support the concept that vardenaﬁl reduces lung inﬂammation out-
come measures in CF-F508del mice. It represents an interesting research tool
to investigate immune responses of airway cells and a promising candidate for
pharmacotherapy of CF.
Supported by the French CF Foundation, Vaincre la Mucoviscidose, and by Fonds
Scientiﬁque de la Recherche (FSR-UCL).
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Objectives: With this open placebo controlled in vivo cross-over study we wanted to
establish the in vivo effect of N-acetylcysteine (NAC) on sputum rheology compared
to normal saline, in order to determine if there is still a place for the use of
N-acetylcysteine inhalations in the daily inhalation treatment of Cystic Fibrosis
patients.
Methods: Visco-elasticity measurements were be done on sputum samples be-
fore and after inhalation of NAC or normal saline. Patients continued to inhale
N-acetylcysteine or normal saline two times per day for one month. After one
month a third sputum sample was collected, visco-elasticity was measured and
compared to the initial values in both groups and between groups. After a wash-
out period of normal saline inhalations during 2 weeks in both groups, patients
in the initial control group were be asked to switch to inhalation of 3ml of NAC
two times per day and the former NAC group continued to inhale two times 4ml
of normal saline during four weeks. After one month the same measurements of
visco-elasticity were done.
15 CF patients started this study (6 drop-outs) (mean age: 23 y, 55.5% female, mean
MBI: 20.4; mean FVC: 93%, mean FEV1: 76%).
Results: There was no effect on elasticity after one dose (Wilcoxon: P = 0.575) and
after a month treatment with NAC (p = 0.889) in comparison with saline, nor was
there an effect on viscocity (after one dose p = 0.78, after one month p = 0.779).
Conclusion: Based on this rheology study, we would no longer recommend the
routine use of NAC in the daily inhalation treatment of cystic ﬁbrosis patients
